Physicochemical and microbiological quality of water from a pilot domestic rainwater harvesting facility in Ireland.

DTC Research Group, Dublin Institute of Technology personnel were commissioned in 2005 by the Department of Environment, Heritage and Local Government in Ireland to assess the feasibility of utilising harvested rainwater to replace treated mains water, for non-potable uses. A pilot project was set up. The project involved the design, installation, commissioning and monitoring of rainwater harvesting facilities in a rural housing development. A monitoring program was carried out to examine the physico-chemical and microbiological quality of the harvested rainwater. Harvested rainwater was sampled monthly and tested. Analysis of the harvested rainwater quality showed a consistently high quality of raw water in general compliance with the requirements of the European Communities (Quality of Bathing Water) Regulations for 100 % of samples and the European Communities (Drinking Water) Regulations, 2007 for 37% of sampling date

Physicochemical and Microbiological quality of harvested rainwater from an agricultural installation in Ireland

Members of DTC Research Group. Dublin Institute of Technology was commissioned in 2005 by the Department of Environment, Heritage and Local Government in Ireland to assess the feasibility of utilising rainwater to replace treated mains water for nonpotable uses. The project involved the design, installation, commissioning and monitoring of rainwater harvesting on a farm. Two monitoring programmes, Regime 1 and Regime 2, examined the physicochemical and microbiological quality of the harvested rainwater. Samples were taken monthly and tested. Regime 1 analysis showed that the microbiological quality of the rainwater from the site did not comply with the requirements of the European Communities Quality of Bathing Water Regulations, while the physicochemical quality complied with both Bathing and Drinking Water Standards with the exception of ammonia and lead. Regime 2 results showed a significant improvement and were compliant with the European Communities Quality of Bathing Water Regulations and showed near compliance with the European Communities Drinking Water Regulation

Pilot Rainwater Harvesting Study Ireland

There are no National Water Quality Standards for Rainwater Harvesting supply in Ireland. The Development Technology Centre (DTC) at the Technological University Dublin was commissioned by the National Rural Water Monitoring Committee in 2005 to assess the feasibility of using rainwater harvesting to supplement treated mains water for non-potable uses. The project involved the design, installation, commissioning and monitoring of rainwater harvesting facilities for rural domestic and agricultural water supply. This paper will present the results from the domestic pilot rwh project. A dual water supply system was designed and installed to use rainwater collected from the roof surface to supplement mains water supply for toilet flushing and out door uses. A series of flow meters and a data logger system were installed to monitor micro component household water usage. Over the 19 month monitoring period, rainwater harvesting resulted in a saving of 20% of the total mains water supplied to the house. Harvested rainwater was tested monthly for physico-chemical and microbiological parameters. All samples complied with EU bathing Water Regulations. Compliance with the more stringent Drinking Water Regulations was achieved for ten of the nineteen sampling dates. Laboratory experiments were conducted using a variety of water related bacteria to determine time required to reduce a bacterial population by 90% at a given temperature. The laboratory experiments showed that hot water systems maintained at adequately high temperatures (60 0C) for 5 minutes effectively reduced the bacterial load from E.coli, Enterococcus faecalis, Pseudomonas sp and Salmonella to zero

The search for the 'next' euphoric non-fentanil novel synthetic opioids on the illicit drugs market: current status and horizon scanning

Purpose: A detailed review on the chemistry and pharmacology of non-fentanil novel synthetic opioid receptor agonists, particularly N-substituted benzamides and acetamides (known colloquially as U-drugs) and 4-aminocyclohexanols, developed at the Upjohn Company in the 1970s and 1980s is presentedMethod: Peer-reviewed literature, patents, professional literature, data from international early warning systems and drug user fora discussion threads have been used to track their emergence as substances of abuse.Results: In terms of impact on drug markets, prevalence and harm, the most significant compound of this class to date has been U-47700 (trans-3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methylbenzamide), reported by users to give short-lasting euphoric effects and a desire to re-dose. Since U-47700 was internationally controlled in 2017, a range of related compounds with similar chemical structures, adapted from the original patented compounds, have appeared on the illicit drugs market. Interest in a structurally unrelated opioid developed by the Upjohn Company and now known as BDPC/bromadol appears to be increasing and should be closely monitored.Conclusions: International early warning systems are an essential part of tracking emerging psychoactive substances and allow responsive action to be taken to facilitate the gathering of relevant data for detailed risk assessments. Pre-emptive research on the most likely compounds to emerge next, so providing drug metabolism and pharmacokinetic data to ensure that new substances are detected early in toxicological samples is recommended. As these compounds are chiral compounds and stereochemistry has a large effect on their potency, it is recommended that detection methods consider the determination of configuration

Association of whole-genome and NETRIN1 signaling pathway-derived polygenic risk scores for Major Depressive Disorder and white matter microstructure in UK Biobank

Background: Major depressive disorder is a clinically heterogeneous psychiatric disorder with a polygenic architecture. Genome-wide association studies have identified a number of risk-associated variants across the genome and have reported growing evidence of NETRIN1 pathway involvement. Stratifying disease risk by genetic variation within the NETRIN1 pathway may provide important routes for identification of disease mechanisms by focusing on a specific process, excluding heterogeneous risk-associated variation in other pathways. Here, we sought to investigate whether major depressive disorder polygenic risk scores derived from the NETRIN1 signaling pathway (NETRIN1-PRSs) and the whole genome, excluding NETRIN1 pathway genes (genomic-PRSs), were associated with white matter microstructure. Methods: We used two diffusion tensor imaging measures, fractional anisotropy (FA) and mean diffusivity (MD), in the most up-to-date UK Biobank neuroimaging data release (FA: n = 6401; MD: n = 6390). Results: We found significantly lower FA in the superior longitudinal fasciculus (β = −.035, p =.029) and significantly higher MD in a global measure of thalamic radiations (β =.029, p =.021), as well as higher MD in the superior (β =.034, p =.039) and inferior (β =.029, p =.043) longitudinal fasciculus and in the anterior (β =.025, p =.046) and superior (β =.027, p =.043) thalamic radiation associated with NETRIN1-PRS. Genomic-PRS was also associated with lower FA and higher MD in several tracts. Conclusions: Our findings indicate that variation in the NETRIN1 signaling pathway may confer risk for major depressive disorder through effects on a number of white matter tracts

Effect of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker initiation on organ support-free days in patients hospitalized with COVID-19

IMPORTANCE Overactivation of the renin-angiotensin system (RAS) may contribute to poor clinical outcomes in patients with COVID-19. Objective To determine whether angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) initiation improves outcomes in patients hospitalized for COVID-19. DESIGN, SETTING, AND PARTICIPANTS In an ongoing, adaptive platform randomized clinical trial, 721 critically ill and 58 non–critically ill hospitalized adults were randomized to receive an RAS inhibitor or control between March 16, 2021, and February 25, 2022, at 69 sites in 7 countries (final follow-up on June 1, 2022). INTERVENTIONS Patients were randomized to receive open-label initiation of an ACE inhibitor (n = 257), ARB (n = 248), ARB in combination with DMX-200 (a chemokine receptor-2 inhibitor; n = 10), or no RAS inhibitor (control; n = 264) for up to 10 days. MAIN OUTCOMES AND MEASURES The primary outcome was organ support–free days, a composite of hospital survival and days alive without cardiovascular or respiratory organ support through 21 days. The primary analysis was a bayesian cumulative logistic model. Odds ratios (ORs) greater than 1 represent improved outcomes. RESULTS On February 25, 2022, enrollment was discontinued due to safety concerns. Among 679 critically ill patients with available primary outcome data, the median age was 56 years and 239 participants (35.2%) were women. Median (IQR) organ support–free days among critically ill patients was 10 (–1 to 16) in the ACE inhibitor group (n = 231), 8 (–1 to 17) in the ARB group (n = 217), and 12 (0 to 17) in the control group (n = 231) (median adjusted odds ratios of 0.77 [95% bayesian credible interval, 0.58-1.06] for improvement for ACE inhibitor and 0.76 [95% credible interval, 0.56-1.05] for ARB compared with control). The posterior probabilities that ACE inhibitors and ARBs worsened organ support–free days compared with control were 94.9% and 95.4%, respectively. Hospital survival occurred in 166 of 231 critically ill participants (71.9%) in the ACE inhibitor group, 152 of 217 (70.0%) in the ARB group, and 182 of 231 (78.8%) in the control group (posterior probabilities that ACE inhibitor and ARB worsened hospital survival compared with control were 95.3% and 98.1%, respectively). CONCLUSIONS AND RELEVANCE In this trial, among critically ill adults with COVID-19, initiation of an ACE inhibitor or ARB did not improve, and likely worsened, clinical outcomes. TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT0273570

Rainwater Harvesting Pilot Project Report

The rainwater harvesting pilot project was commissioned by the National Rural Water Monitoring Committee in 2005 to assess the feasibility of supplementing treated mains water used for non-potable purposes. The project involved the design, installation, commissioning and monitoring of rainwater harvesting facilities in a rural housing development in County Carlow and in a 250-acre livestock farm in County Meath. Construction was carried out between 2005-2007